DXB

1.28%

38.5¢ dimerix limited

Jealous.

First 65 Last

Share
Profile

Follow
UncleFesta

1,572 Posts.

547

05/01/24

11:53

Post #: 71740172
Share

Originally posted by vrs37: ↑

dr manhattan is right, this is a biased echo chamber. With lot of self-righteous waffle.
by “misrepresentation of facts” what you really mean is misrepresentation of your version of the facts singhu .
again you’re in denial or can’t read so let’s dig into the diabetes kidney disease a bit more and cut through your fantasy
# “Dimerix drug fails to best placebo in diabetes kidney disease study” as reported S&P global market intelligence on 15/9/2020. Clear and 100% correct . If u don’t like “flopped” I can use failed or flunked. Nobody except gullible investors falls for the questionable attempt to distract from the overall negative result by presenting it as a triumph via a post hoc p- hacked subgroup analysis. (Look up p- hacking if you don’t know what it is). It says something that 3 years after communicating results to market this study is not discoverable on any reputable scientific abstract or published paper. The results page in clinical trials .gov under this study remains blank. Why might that be Singhu?
# ANN 7/6/22: “new” diabetes trial announced. Protocol “currently being finalised”, study “expected to commence in Q4 2022”
# 4c 27/7/22: same thing, study to “commence “late 2022”
# 4c 27/10/22: plan to “initiate study in late 2022”,
#AGM 29/11/22- slide 13, “pre IND planned with FDA in Q1 2023”.
# whole of 2023…. Nothing. This “new” trial has vanished from face of earth. Nothing traceable on any trial platform either.
Come clean Singhu- there’s no diabetes trial is there. It doesn’t exist, never has. You really think it ever will ? Do you think the pre-IND mtg ever happened? If it did, what feedback did they get from fda that prevented an announcement? Care to venture Singhu? Based on these ANNs through 2022 about the trial is it possible some people got breadcrumbed and bought in in 2022 thinking this diabetes trial was really near term.

COPD? Good luck with that one. As I posted before, the Dmx asset is reported to be il8 blocker. Human (as opposed to mouse) copd trials already show il8 inhibition to have weak efficacy or toxic . That’s why some big Pharma companies have abandoned those assets. A 10 minute search will show this. Still optimistic?

Expand

Jealous.

DXB Price at posting: 25.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 13 more messages in this thread...

First 65 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 38.5¢		Change -0.005(1.28%)		Mkt cap ! $214.4M

Open	High	Low	Value	Volume
39.0¢	39.0¢	37.0¢	$503.5K	1.322M

Buyers (Bids)

No.	Vol.	Price($)
2	26318	38.0¢

Sellers (Offers)

Price($)	Vol.	No.
39.0¢	170072	6

View Market Depth

No.	Vol.	Price($)
2	26318	0.380
6	228354	0.375
6	178335	0.370
4	86518	0.365
4	27499	0.360

Price($)	Vol.	No.
0.390	170072	6
0.395	90849	3
0.400	144109	4
0.405	86528	4
0.410	56400	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

DXB (ASX) Chart

Jealous.

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Jealous.

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News